Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease Poster バセドウ病眼症の治療を目的とした完全ヒト型抗IL-6抗体TOUR006のフェーズ2b試験における用量選択を支援するためのシミュレーション Certara2025年2月7日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Certara2024年11月22日
Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis. ポスター Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis. Certara2024年11月22日
Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials Poster Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials Certara2024年11月22日
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Poster Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Certara2024年11月22日
A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model Poster A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model Certara2024年11月22日
Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation Poster Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation Certara2024年11月22日
Building Automated Pharmacometrics Analysis Workflows in R with NMsim Poster Building Automated Pharmacometrics Analysis Workflows in R with NMsim Certara2024年11月22日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia Certara2024年11月22日
Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites Poster Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites Certara2024年11月22日
